Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Dr. Alice Bernard-Tessier receives a Young Investigator Award by the Prostate Cancer Foundation
Based in the United States, the Prostate Cancer Foundation is one of the world’s most influential organisations dedicated to prostate cancer research. It has awarded Dr. Alice Bernard-Tessier, an oncologist at Gustave Roussy currently in the United States as part of a partnership with the Dana-Farber Cancer Institute, a Young Investigator Award. This prize, presented for the first time to a French researcher, recognises her project aimed at better understanding the mechanisms of resistance to a targeted therapy to develop new therapeutic strategies.
Published on
Based in the United States, the Prostate Cancer Foundation is one of the world’s most influential organisations dedicated to prostate cancer research. It has awarded Dr. Alice Bernard-Tessier, an oncologist at Gustave Roussy currently in the United States as part of a partnership with the Dana-Farber Cancer Institute, a Young Investigator Award. This prize, presented for the first time to a French researcher, recognises her project aimed at better understanding the mechanisms of resistance to a targeted therapy to develop new therapeutic strategies.
Founded in 1993, the Prostate Cancer Foundation is a major player in prostate cancer research. It has already supported more than 2,250 programmes and contributed to the development of 14 new therapies that have significantly improved the prognosis for men affected by this cancer.
Dr. Alice Bernard-Tessier is an oncologist at Gustave Roussy and a specialist in prostate cancer. She is currently a postdoctoral researcher at the Dana-Farber Cancer Institute, Harvard University, in the laboratory of Dr. Himisha Beltran, where she has just received this Young Investigator Award.
This prestigious award, amounting to USD 75,000 per year for three years and cofounded by the CRIS Cancer Foundation, will support Dr. Bernard-Tessier’s research project dedicated to understanding the mechanisms of resistance that arise in some patients with hormone-resistant prostate cancer treated with PARP inhibitors, a targeted therapy.
Understanding resistance mechanisms
“PARP inhibitors are treatments that target a vulnerability in tumour cells related to DNA repair. They have proven effective in patients with metastatic, hormone-resistant prostate cancer carrying a BRCA1/2 mutation. However, in some cases, this treatment loses its effectiveness over time. The aim of my research project is to combine genomic, molecular and clinical data from the TRITON3 trial to identify the mechanisms responsible for treatment failure in certain patients,” explains Dr. Bernard-Tessier.
The results of this work could help guide treatment decisions and lead to the development of new therapeutic strategies to improve outcomes for patients with metastatic prostate cancer.
This international distinction is awarded for the first time to a French researcher. Gustave Roussy actively supports its young clinicians and scientists by offering dedicated development programmes and encouraging them to train at the highest level through collaborations with leading international centres such as the Dana-Farber Cancer Institute at Harvard University. The aim: to foster and support emerging talents in oncology.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
